Cyprotex enables and enhances the prediction of human exposure, clinical efficacy and toxicological outcome of a drug or chemical. Cyprotex specialises in customizable vitro and in silico ADME-Tox services including drug discovery screening, DDI studies during pre-clinical and clinical development, mechanistic in vitro human / animal toxicity models, and PBPK/QSAR modelling.